|
Video: What is a Stock Split?
|
|
PDS Biotechnology is an immunotherapy company developing molecularly targeted immunotherapies designed to overcome the limitations of existing immunotherapy and vaccine technologies. Co.'s T cell activating platforms designed to train the immune system to attack and destroy disease; Versamune®, and Versamune plus PDS0301 for treatments in oncology; and Infectimune, for treatments in infectious disease. Co. develops targeted product candidates to treat several cancers including Human Papillomavirus-associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Co.'s infectious disease candidates are of potential interest for use in COVID-19 and universal influenza vaccines. According to our PDS Biotechnology stock split history records, PDS Biotechnology has had 1 split. | |
|
PDS Biotechnology (PDSB) has 1 split in our PDS Biotechnology stock split history database. The split for PDSB took place on March 18, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of PDSB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as PDS Biotechnology conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PDS Biotechnology stock split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PDS Biotechnology shares, starting with a $10,000 purchase of PDSB, presented on a split-history-adjusted basis factoring in the complete PDS Biotechnology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/01/2015 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$258.80 |
|
End price/share: |
$2.65 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.98% |
|
Average Annual Total Return: |
-41.47% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$102.25 |
|
Years: |
8.56 |
|
|
|
Date |
Ratio |
03/18/2019 | 1 for 20 |
|
|